BNP Paribas Knock-Out MRK/ DE000PH2F1V4 /
13.11.2024 16:52:11 | Изменение-0.06 | Бид17:12:11 | Предложение17:12:11 | Базовый актив | Цена исполнения | Дата истечения | Тип опциона |
---|---|---|---|---|---|---|---|
2.91EUR | -2.02% | 2.94 Величина цены спроса: 48,000 |
2.95 Величина цены предложения: 48,000 |
Merck and Co Inc | 67.5826 USD | 31.12.2078 | Call |
GlobeNewswire
31.07
Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease
GlobeNewswire
17.07
Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease a...
GlobeNewswire
11.06
Biora Therapeutics Announces Presentation on the BioJet™ Systemic Oral Delivery Platform at the Next...
GlobeNewswire
06.06
Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepin...
GlobeNewswire
28.05
Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD
GlobeNewswire
23.05
atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors
GlobeNewswire
16.05
Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
14.05
IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights
GlobeNewswire
08.05
C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
GlobeNewswire
24.04
IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Onc...
GlobeNewswire
15.04
IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness
- Первая страница
- Назад
- 1
- 2
- 3
- 4
- Следующий
- Последняя страница